What is the latest price of Mitotane in 2025? Is there a downward trend in prices?

Mitotane is a special anti-tumor drug used to treat adrenocortical cancer (ACC). The domestic original drug is currently on the market, but due to its short time on the market, the specific price is not yet clear, and it has not yet been included in medical insurance. Therefore, when patients purchase medicines in the country, they need to consult local hospital pharmacies for the latest price information. At the same time, because they are not covered by medical insurance, patients need to bear higher drug purchasing costs at their own expense, which may prompt some patients to seek overseas drug purchasing channels.

In foreign markets, the original version of mitotane is more common, mainly including the European version and the Turkish version, and the specification is usually 500mg*100 tablets. Currently, the selling price of these original drugs is about 9,000 yuan, but the specific price may fluctuate depending on the region, exchange rate and drug purchase channels. In addition, some countries and regions may have price adjustments, but overall, the prices of original drugs remain at a high level, and there is no obvious downward trend in the short term.

In addition to original drugs, there are also generic drugs available in overseas markets, such as the Lao version of mitotane. The ingredients of these generic drugs are basically the same as those of the original drugs, but the price is relatively cheaper. The price of each box of 500mg*100 tablets may be around 2,000 yuan. For patients with limited financial conditions, generic drugs may be a more cost-effective option, but they still need to be cautious before purchasing to ensure that the quality of the drugs is reliable and obtained through formal channels to ensure the safety of the drugs.
Overall, the price of mitotane will still be at a relatively high level in 2025, especially since the price of the original drug does not fluctuate much and will be difficult to drop significantly in the short term. However, with the gradual promotion of generic drugs and intensifying market competition, some patients may be more inclined to choose lower-priced generic drugs. In the future, if mitotane is included in medical insurance or more generic drugs are launched, the price is expected to gradually drop, reducing the financial burden on patients.
Reference: https://go.drugbank.com/drugs/DB00648